IS IT SAFE? SAFETY SURVEILLANCE THROUGH THE ANTIRETROVIRAL PREGNANCY REGISTRY

WCWD2817

PROGRAM DESCRIPTION: This is a one-hour webinar with a single presenter supported by two additional expert discussants that will participate in the planned question and answer component of the webinar. The goal of this training is to increase the number providers caring for pregnant women living with HIV willing to enroll their patients in the Antiretroviral Pregnancy Registry (APR) as early in pregnancy as possible in order to maximize the validity of the APR data.

AGENDA

WHEN: Thursday, March 2, 2017
TIME: 1:00 pm – 2:00 pm ET 12:00 pm – 1:00 pm CT
11:00 am – 12:00 pm MT 10:00 am – 13:00am PT

PRESENTER:

- William Short, MD, MPH, AAHIVS University of Pennsylvania, Philadelphia, Pennsylvania

WITH DISCUSSION AND COMMENTARY BY:

- Lynne Mofenson, MD, Elizabeth Glaser Pediatric AIDS Foundation
- Hugh Tilson, MD, DrPH. Gillings School of Global Public Health, University of North Carolina-Chapel Hill, Chapel Hill, North Carolina

OBJECTIVES:
At the end of this webinar, participants will:

- Describe three objectives of the Antiretroviral Pregnancy Registry (APR). (15 minutes)
- List two key findings from analysis of APR data. (15 minutes)
- Describe four steps to report a drug exposure to the APR. (30 minutes, with Q&A session)

FACULTY/ CREDENTIALS:	**Presenter:**	Dr. William R. Short Associate Professor of Medicine University of Pennsylvania
	Discussants:	Dr. Hugh Hana Tilson Adjunct Professor University of North Carolina Gillings School of Public Health
		Dr. Lynne Mofenson Senior HIV Technical Advisor Elizabeth Glaser Pediatric AIDS Foundation

ORIGINATION DATE **EXPIRATION DATE:**

WC – 3/02/2017 - 4/02/2017
WD - 4/02/2017 - 4/02/2017

URL:	**TBD**
HARDWARE/SOFTWARE:	Computer Hardware; Internet connection; Browser
MATERIALS:	None
TARGET AUDIENCE:	Physicians, Registered Nurses
PREREQUISITES:	None
FORMAT:	webcast, web-on-demand
CONTACT INFORMATION:	Office of Mary Jo Hoyt, (973) 972-9230

ACCREDITATION STATEMENTS:

CME activities with Joint Providers: This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Centers for Disease Control and Prevention and the **FXB Center, Rutgers University School of Nursing.** The Centers for Disease Control and Prevention is accredited by the (ACCME®) to provide medical education for physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The Centers for Disease Control and Prevention designates this **enduring material** for a maximum of **1.0** *AMA PRA Category 1 Credits*™.

CNE: The Centers for Disease Control and Prevention is accredited as a provider of Continuing Nursing Education by the American Nurses Credentialing Center's Commission on Accreditation.

This activity provides **1.0** contact hours.

CEU: The Centers for Disease Control and Prevention is authorized by IACET to offer **0.1** CEU's for this program.

DISCLOSURE: In compliance with continuing education requirements, all presenters must disclose any financial or other associations with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters as well as any use of unlabeled product(s) or product(s) under investigational use.

CDC, our planners, our presenters, and their spouses/partners wish to disclose they have no financial interests or other relationships with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters with the following exceptions. Dr. Tilson wishes to disclose paid consultancies with the pharmaceuticals Novartis, GSK, Bristol-Myers Squibb, Merck, and Gilead Sciences. Dr. Tilson is also paid as the Senior Consultant to the Antiretroviral Pregnancy Registry (APR). Dr. Short wishes to disclose paid consultancy and speaker fees for Janssen Therapeutics and paid consultancy for Gilead Sciences.

Planning committee discussed conflict of interest with Dr. Tilson and Dr. Short to ensure there is no bias.

Presenters will be discussing potential off labeled use of drugs covered by APR.

The Antiretroviral Pregnancy Registry (APR) monitors antiretroviral (ARV) exposures during pregnancy. By registry definition, this includes monitoring of the off-label use of FDA-approved ARVs during pregnancy. *The APR does not make specific recommendations related to the use of specific ARVs during pregnancy.*

The Centers for Disease Control and Prevention and the FXB Center, Rutgers University School of Nursing are jointly providing the CNE for this activity**.**

CDC did not accept commercial support for this activity.

To receive continuing education (CE):

Complete the activity
Complete the Evaluation at www.cdc.gov/TCEOnline
Pass the posttest at 75% at www.cdc.gov/TCEOnline

FEES: No fees are charged for CDC's CE activities.